Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc filed a Form 6-K for the month of January 2023. The filing contains a January 31, 2023 press release regarding changes to the company’s board. Haleon is a global consumer-health company operating across oral health, pain relief, respiratory health, digestive health, vitamins, minerals and supplements, and other categories.
Financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
- John Young, a non-executive director and Pfizer representative, will step down effective February 28, 2023.
- David M. Denton, Pfizer’s Chief Financial Officer and Executive Vice President, will succeed him as a non-executive director and Pfizer representative effective March 1, 2023.
- Denton is not considered independent under the UK Corporate Governance Code because he is one of Pfizer’s representative directors under the Pfizer Relationship Agreement.
- Young is not entitled to remuneration or loss-of-office payments in connection with his departure.
Guidance, outlook, risks and unusual items
The filing contains no financial guidance, operating outlook, identified contingencies, or specific risk disclosures. Management commentary is limited to acknowledging Young’s contributions and welcoming Denton’s healthcare and financial experience. The company states that no additional matters require disclosure under Rule 9.6.13R of the UK Listing Rules.
Investor verification points
- Verify the effective dates of Young’s departure and Denton’s appointment.
- Assess the implications of Denton’s non-independent status and Pfizer’s continuing board representation.
- Consult Haleon’s financial filings separately for performance, leverage, liquidity, guidance, and risk information, which are not included in this Form 6-K.